Nomura's research report indicates that JD HEALTH's pharmaceutical sales momentum is strong and operating profit remains robust. However, a decrease in non-operating income has negatively impacted net profit, leading the broker to lower its target price from HKD80 to HKD67 while maintaining a Buy rating.
